Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | QPCT | Q16769 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252088 | 0.79 | HTT (0.54) | SMN1; SMN2LMNAQPCTL3MBTL1HTT | |
| SCHEMBL31252074 | 0.78 | HTT (0.51) | SMN1; SMN2LMNAQPCTL3MBTL1HTT | |
| SCHEMBL17410493 | 0.78 | RAB9A (0.52) | SMN1; SMN2LMNAQPCTL3MBTL1HTT | |
| SCHEMBL1568420 | 0.76 | L3MBTL1 (0.53) | SMN1; SMN2LMNAQPCTL3MBTL1HTT | |
| SCHEMBL12742373 | 0.75 | HSD17B10 (0.67) | SMN1; SMN2LMNAHTTMAPTNPC1 | |
| SCHEMBL28473741 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAQPCTHTTKAT2B | |
| SCHEMBL13055383 | 0.75 | LMNA (0.80) | SMN1; SMN2LMNAL3MBTL1HTTKAT2B | |
| SCHEMBL31311383 | 0.74 | KAT2B (0.58) | SMN1; SMN2LMNAL3MBTL1HTTKAT2B | |
| SCHEMBL14416038 | 0.74 | QPCT (0.67) | QPCTMAPTGAA | |
| SCHEMBL170570 | 0.74 | LMNA (0.60) | SMN1; SMN2LMNAL3MBTL1HTTKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2307417-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | HCRTR1, HCRTR2, NPY5R | SMN1; SMN2 3184/4885LMNA 3348/4885QPCT 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.